News & Updates
Showing Endocrinology articles
Showing
Roflumilast serves up weight-loss benefit for patients with psoriasis
In the treatment of patients with psoriasis, the phosphodiesterase (PDE)-4 inhibitor roflumilast has been found to also induce weight loss.
Roflumilast serves up weight-loss benefit for patients with psoriasis
20 Oct 2023
Newly diagnosed T2D linked to earlier CVD events
A new diagnosis of type 2 diabetes (T2D) raises the risk of cardiovascular disease (CVD) development within 10 years in both men and women and across age groups, particularly among younger patients, reveals a recent study.
Newly diagnosed T2D linked to earlier CVD events
20 Oct 2023
GLP-1RA, SGLT2i superior to DPP-4i at preventing stroke, death in T2D patients
Among type 2 diabetes (T2D) patients with and without comorbid cardiovascular disease, those who have been newly initiated to glucagon-like peptide-1 receptor agonists (GLP-1RA) or sodium-glucose cotransporter 2 inhibitors (SGLT2i) appear to enjoy greater reductions in the risks of stroke and death when compared with new users of dipeptidyl peptidase-4 inhibitors (DPP-4i), suggests a study.
GLP-1RA, SGLT2i superior to DPP-4i at preventing stroke, death in T2D patients
19 Oct 2023
Age, sex, prior complaints predict GI symptoms in adults with new-onset diabetes
Nearly half of individuals with a newly diagnosed type 1 (T1D) or type 2 diabetes (T2D) suffer from gastrointestinal (GI) symptoms, according to a study presented at EASD 2023. These GI adverse events that are associated with glucose-lowering medications occur more frequently among those with already existing GI symptoms prior to treatment initiation.
Age, sex, prior complaints predict GI symptoms in adults with new-onset diabetes
18 Oct 2023
Is there a need to re-evaluate HbA1c cutoff in premenopausal women?
In an analysis of over a million individuals in England, women aged <50 years had a markedly lower HbA1c distribution than men, suggesting that the application of the current HbA1c reference range may lead to underdiagnosis of type 2 diabetes (T2D) in premenopausal women.
Is there a need to re-evaluate HbA1c cutoff in premenopausal women?
18 Oct 2023
Dapagliflozin cuts HbA1c in paediatric T2D
Dapagliflozin reduced HbA1c by 1.03 percentage points more than placebo in children and adolescents with type 2 diabetes (T2D), while saxagliptin showed no significant reduction vs placebo in the phase III T2NOW trial presented at EASD 2023.
Dapagliflozin cuts HbA1c in paediatric T2D
17 Oct 2023
Finerenone confers cardiorenal benefits in Chinese CKD, T2D patients
In the subgroup analysis of the phase III FIGARO-DKD trial, the selective nonsteroidal mineralocorticoid receptor antagonist finerenone conferred cardiorenal benefits in Chinese patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The findings were consistent with that observed in the overall cohort.
Finerenone confers cardiorenal benefits in Chinese CKD, T2D patients
16 Oct 2023
Shorter height, smaller hips linked to higher T2D risk
Most adiposity markers are positively associated with incident type 2 diabetes (T2D), but waist to height ratio (WHtR) shows the most robust association and is a better predictor of T2D risk.